01 March 1999
Molecular and therapeutical aspects of the blood platelet receptors antagonists
Marcin Różalski, Magdalena Boncler, Bogusława Więcławska, Cezary WatałaMed Sci Monit 1999; 5(2): RA357-375 :: ID: 505175
Abstract
Many new, potent, antiplatelet agents belonging to the group of platelet receptors antagonists became recently available for clinical evaluation and intervention. Amongst platelet inhibitors of a newer generation including inhibitors of platelet adhesion, inhibitors of specific platelet agonist-receptor interactions (antithrombins, fibrinogen receptor antagonists, thromboxane A2, receptor antagonists, ADP receptor blockers like ticlopidine and clopidogrel, or inhibitors of thromboxane synthase and arachidonic acid metabolism), only the antagonists of platelet receptors have been demonstrated to allow more global interruption of both the initial and final steps of platelet-dependent prothrombotic events. Due to the considerable progress in the development of novel agents aimed to reducing platelet-derived thrombosis, various antiplatelet drugs have been invented, which are rationally based on interrupting specific sites in the sequence of platelet activation, adhesion and aggregation. The antagonists of platelet receptors focus considerable attention, because they are able to directly interfere with the interactions between blood platelets and their ligands. The common feature of these agents is that they are designed to interrupt platelet response at the very initial stage of platelet activation - when the 'outside-in receptor-mediated' triggers signal transduction in platelet cytoplasm. In that sense, the antagonists of platelet receptors are believed to represent quite a new approach to the treatment of platelet thrombosis.
Keywords: antiplatelet drugs, peptidomimetics, monoclonal antibodies, RGD-derived ligands, peptidomimetics
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952